PER 13.0% 13.0¢ percheron therapeutics limited

DMD Phase 2 Results in Q4 = Potential 5000% Gem, page-269

  1. 173 Posts.
    lightbulb Created with Sketch. 37
    I think Sarepta alredy watching this one very closely and i wouldnt be surprised if there is an Deal or even a buyout by SRPT

    Antisense director Bill Goolsbee was Sarepta’s chairman and no doubt he has some decent tips on drug commercialisation.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.